Nitazene Control Act of 2025

Bill Number: H.R. 5415
Origin Chamber: House
Congress: 119th Congress, Session 1
Policy Area: Crime and Law Enforcement
Status: Introduced
Latest Action: 2025-09-16: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Last Updated: 2026-05-12T08:06:18Z

AI-Generated Summary

Purpose

The Nitazene Control Act of 2025 aims to permanently classify a group of synthetic opioids known as nitazenes (a type of 2-benzylbenzimidazole opioid) as Schedule I controlled substances under the Controlled Substances Act. This is intended to address their high potency—some are stronger than fentanyl—their role in illicit drug overdoses, and the need to prevent new variants from entering the drug supply.

Key Provisions

Findings Section: Congress recognizes nitazenes as highly potent synthetic opioids first developed in the 1950s, with no accepted medical use and high abuse potential. They have been temporarily scheduled by the Drug Enforcement Administration (DEA) and are contributing to fatal overdoses. A class-wide permanent ban is seen as essential for enforcement and public health, while noting existing research pathways under laws like the HALT Fentanyl Act.
Scheduling Amendment: Adds nitazenes to Schedule I of the Controlled Substances Act (21 U.S.C. 812(c)), defining them broadly by chemical structure (e.g., modifications at specific positions on the benzimidazole ring) and their activity as mu-opioid receptor agonists (substances that activate opioid receptors in the brain, leading to pain relief but also addiction and overdose risks). Examples include etonitazene, clonitazene, and others.
Transition from Temporary Scheduling: Any nitazenes previously placed under temporary Schedule I status become permanently scheduled upon enactment.
Research Safeguards: Clarifies that the law does not allow new research on these substances without proper DEA registration and compliance with scheduling rules.

Significant Changes to Existing Law

Shifts certain nitazenes from temporary to permanent Schedule I status, eliminating the need for repeated emergency scheduling by the DEA.
Introduces a class-wide definition to cover current compounds and future analogs (similar chemical variants), preempting "designer drugs" that evade narrower bans.
Builds on prior laws like the HALT Fentanyl Act by preserving research access for registered entities but reinforces strict controls.

Potential Impacts

Government Agencies: Enhances the DEA's and law enforcement's ability to seize and prosecute related substances more efficiently, reducing administrative burdens from frequent re-scheduling. Public health agencies may see fewer overdose cases due to better control of the illicit supply.
Citizens: Could reduce access to these highly dangerous opioids in illegal markets, potentially lowering overdose deaths (nitazenes have been linked to poisonings). However, it may limit legitimate medical or research uses without proper approvals.
International Relations: Strengthens U.S. efforts to combat global synthetic opioid trafficking, possibly influencing international drug control treaties or cooperation with countries producing precursors, though no direct foreign policy changes are specified.

Main Stakeholders Affected

Law Enforcement and DEA: Gain streamlined tools for enforcement against evolving drug threats.
Public Health and Medical Communities: Benefit from overdose prevention but must navigate stricter regulations for any research on these potent substances.
Researchers and Pharmaceutical Industry: Face barriers to new studies unless registered with the DEA; existing pathways (e.g., under the HALT Fentanyl Act) remain available for approved purposes.
Individuals and Communities: People struggling with opioid addiction or at risk of exposure to contaminated drugs may experience indirect protection, while illicit drug users face heightened legal risks.

Notable Legal, Constitutional, or Political Implications

Legal: Provides a clear statutory basis for federal prosecutions, reducing reliance on administrative actions that could be challenged in court. The broad class definition may raise questions about overreach if it inadvertently includes non-abusable substances, but the structural and functional criteria aim to target only harmful opioids.
Constitutional: Aligns with Congress's authority to regulate interstate commerce and public health under the Commerce Clause; no apparent conflicts with due process or free speech, as it focuses on substance control rather than individual rights.
Political: Represents a bipartisan response to the ongoing opioid crisis (introduced by representatives from both parties), potentially building momentum for further drug policy reforms. It underscores a shift toward proactive, class-based scheduling to address synthetic drug innovation, which could influence future legislation on emerging threats.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Vindman, Eugene Simon [D-VA-7]

Cosponsors (30)

Rep. Baumgartner, Michael [R-WA-5], Rep. Harris, Andy [R-MD-1], Rep. Fitzpatrick, Brian K. [R-PA-1], Rep. Davis, Donald G. [D-NC-1], Rep. McCormick, Richard [R-GA-7], Rep. Goldman, Daniel S. [D-NY-10], Rep. Taylor, David J. [R-OH-2], Rep. Mackenzie, Ryan [R-PA-7], Rep. Harrigan, Pat [R-NC-10], Rep. Kelly, Mike [R-PA-16], Rep. Ross, Deborah K. [D-NC-2], Rep. Thompson, Glenn [R-PA-15], Rep. Onder, Robert F. [R-MO-3], Rep. Bresnahan, Robert P. [R-PA-8], Rep. Lawler, Michael [R-NY-17], Rep. Houlahan, Chrissy [D-PA-6], Rep. Carey, Mike [R-OH-15], Rep. Neguse, Joe [D-CO-2], Rep. Gill, Brandon [R-TX-26], Rep. Pfluger, August [R-TX-11], Rep. Liccardo, Sam T. [D-CA-16], Rep. Lee, Susie [D-NV-3], Rep. Schmidt, Derek [R-KS-2], Rep. Salazar, Maria Elvira [R-FL-27], Rep. Baird, James R. [R-IN-4], Rep. Suozzi, Thomas R. [D-NY-3], Rep. Fine, Randy [R-FL-6], Rep. Fry, Russell [R-SC-7], Rep. Goodlander, Maggie [D-NH-2], Rep. Van Epps, Matt [R-TN-7]

Recent Actions

2025-09-16: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-09-16: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-09-16: Introduced in House
2025-09-16: Introduced in House

Bill Versions

Nitazene Control Act of 2025 — issued 2025-09-16 — PDF (5 pages)